Association of RXR-Gamma Gene Variants with Familial Combined Hyperlipidemia: Genotype and Haplotype Analysis

Table 3

Haplotype frequencies in all FCHL affected and controls for the five analysed SNPs.

ID	Haplotypes	Case (𝑛=312)	Control (𝑛=156)	𝑃𝑐 value	Odds ratio [95% CI]
1	CGCGC	0.130 (41)	0.134 (21)	0.862126	1.052 [0.594~1.861]
2	CGTAG	0.070 (22)	0.077 (12)	0.913662	0.960 [0.463~1.994]
3	CGTGC	0.032 (10)	0.058 (9)	0.215309	0.558 [0.219~1.420]
4	CTCGC	0.077 (24)	0.09 (14)	0.780397	0.907 [0.456~1.804]
5	CTTAC	0.038 (12)	0.013 (2)	0.119377	3.081 [0.696~13.636]
6	CTTAG	0.189 (59)	0.115 (18)	0.048031	2.020 [1.137~3.589]
7	CTTGC	0.051 (16)	0.096 (15)	0.101978	0.547 [0.263~1.137]
8	TGTGC	0.054 (17)	0.135 (21)	0.02361	0.386 [0.196~0.761]
9	TTTGC	0.234 (73)	0.220 (34)	0.457251	1.194 [0.748~1.905]

CI: confidence interval; SNPs: single nucleotide polymorphisms; FCHL: familial combined hyperlipidemia.
All frequencies <0.03 have been ignored in analysis. Loci chosen for hap-analysis: rs1128977, rs2651860, rs2134095, rs283696, and rs10918169.
The number of chromosomes valid for analysis is reported in parentheses (312 out of 384 chromosomes for the 192 FCHL affected and 156 out of 238 chromosomes for the 119 controls). Global 𝜒² is 18.905838 while df = 8. Fisher’s 𝑃 value is 0.015506; Pearson’s 𝑃 value is 0.015371.